Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation

A PRISMA-compliant article

Seung Min Kim, MD, PhD, Eun-Tae Jeon, MS, Jin-Man Jung, MD, PhD, Ji-Sung Lee, PhD

Abstract

Background and Purpose: This study aimed to evaluate the comparative efficacy and safety of 4 non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians with non-valvular atrial fibrillation in real-world practice through a network meta-analysis of observational studies.

Methods: We searched multiple comprehensive databases (PubMed, Embase, and Cochrane library) for studies published until August 2020. Hazard ratios and 95% confidence intervals were used for the pooled estimates. Efficacy outcomes included ischemic stroke (IS), stroke/systemic embolism (SSE), myocardial infarction (MI), and all-cause mortality, and safety outcomes included major bleeding, gastrointestinal (GI) bleeding, and intracerebral hemorrhage (ICH). The P score was calculated for ranking probabilities. Subgroup analyses were separately performed in accordance with the dosage range of NOACs (“standard-” and “low-dose”).

Results: A total of 11, 6, and 8 studies were allocated to the total population, standard-dose group, and low-dose group, respectively. In the total study population, edoxaban ranked the best in terms of IS and ICH prevention and apixaban ranked the best for SSE, major bleeding, and GI bleeding. In the standard-dose regimen, apixaban ranked the best in terms of IS and SSE prevention. For major bleeding, GI bleeding, and ICH, edoxaban ranked the best. In the low-dose regimen, edoxaban ranked the best for IS, SSE, GI bleeding, and ICH prevention. For major bleeding prevention, apixaban ranked best.

Conclusions: All 4 NOACs had different efficacy and safety outcomes according to their type and dosage. Apixaban and edoxaban might be relatively better and more well-balanced treatment for Asian patients with non-valvular atrial fibrillation.

Abbreviations: AF = atrial fibrillation, CI = confidence interval, GI = gastrointestinal, ICH = intracerebral hemorrhage, IS = ischemic stroke, NMA = network meta-analysis, NOAC = non-vitamin K antagonist, NVAF = non-valvular atrial fibrillation, PSM = propensity score matching, RCT = randomized clinical trial, SSE = stroke/systemic embolism.

Keywords: network meta-analysis, nonvalvular atrial fibrillation, oral anticoagulants, outcome

Editor: Ardavan Khoshnood.

The authors declare the following potential conflicts of interest concerning the research, authorship, and/or publication of this article. J-MJ has received the following: lecture honoraria from Pfizer, Sanofi-Aventis, Otsuka, Dong-A, and Hanmi Pharmaceutical Co., Ltd.; and consulting fees from Daewoong Pharmaceutical Co., Ltd. The authors declare that the research was conducted without any commercial or financial relationships that could be construed as potential conflicts of interest.

Funding sources: This work was supported by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (Project Number: 9991007421, KMDF_PR_20200901_0187).

Supplemental Digital Content is available for this article.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

a Department of Neurology, Veterans Health Service Medical Center, Seoul, b Department of Neurology, Korea University Ansan Hospital, Korea University College of Medicine, c Korea University Zebrafish Translational Medical Research Center, Ansan, d Clinical Research Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

* Correspondence: Ji-Sung Lee, Clinical Research Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South of Korea (e-mail: toto096a@gmail.com).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Kim SM, Jeon ET, Jung JM, Lee JS. Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: A PRISMA-compliant article. Medicine 2021;100:32(e26883).

Received: 29 January 2021 / Received in final form: 30 June 2021 / Accepted: 21 July 2021
http://dx.doi.org/10.1097/MD.00000000000026883
1. Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence is rising continuously with an aging population.[1] AF is considered an important risk factor for ischemic stroke (IS), congestive heart failure, and all-cause mortality.[2,3] Although the prevalence and lifetime risk of AF in Asian populations is lower than that in Western populations, the burden in Asian populations may actually be higher due to the rapid increase of the elderly population in most Asian countries and a higher annual risk and burden of stroke, although both populations share similar risk factor profiles.[4,5] In fact, Asians have a tendency to have higher CHADS2 or CHA2DS2-VASc scores than the Caucasian population.[6,7] This may be explained by the higher proportion of Asian patients with a previous stroke/transient ischemic attack, which is an important predictor[8] for future stroke. Of note, Asian populations also have a higher risk of hemorrhagic stroke and major bleeding with anticoagulants than non-Asians.[9] Moreover, good quality of long-term warfarin therapy has not been able to be adequately sustained to prevent recurrent stroke in Asians.[10] Thus, non-vitamin K antagonist oral anticoagulants (NOACs) have become the standard oral anticoagulants in Asian patients with AF.[11] Although the effect and safety of NOACs over warfarin seem to be relatively superior in Asians than in non-Asians,[12,13] the bleeding rates with NOACs are also higher in Asian than in non-Asian patients. Therefore, it is critical to investigate which of the 4 NOACs have the best efficacy and safety profiles and to determine the proper dosage for Asian populations in the era of NOACs.

Information gathered from real-world clinical practice is needed to better understand the implementation and impact of specific interventions because data from randomized clinical trials (RCTs) are not always applicable to real-life settings. Although previous pair-wise and network meta-analyses (NMAs)[11–15] have compared the efficacy and safety outcomes of NOACs and warfarin in Asian patients, there has been strong evidence which of them was decided to be better treatment. Specifically, novel data on edoxaban have not been corroborated, observational and clinical trial datasets have been coalesced, and separate analyses according to dose regimens have not been included in pooled results. Additionally, 3 nationwide claims studies recently have reported real-world direct comparisons in terms of the efficacy and safety of the 4 NOACs versus warfarin in the Japanese,[16] Korean,[17] and Taiwanese[18] populations. Although recent study compared the efficacy and safety of 4 NOACs, including 5 RCTs and 12 observational studies,[13] it seems at a higher risk of heterogeneity in terms of study design and enrolled population because that study performed pooled analysis of RCTs and non-RCTs from real-world data.

Therefore, we conducted an updated systematic review and NMA to evaluate the comparative efficacy and safety of all 4 NOACs versus warfarin according to dose regimens.

2. Methods

2.1. Data sources and search strategy

We searched multiple comprehensive databases (Pubmed, Embase, and Cochrane library) for studies that compared the effects of NOACs in terms of IS and thromboembolism prevention in Asian populations with non-valvular AF (NVAF). This search was conducted for studies published from the inception of the databases until August 2020 using the following keywords and their derivatives: “atrial fibrillation,” “warfarin,” “NOAC,” “dabigatran,” “rivaroxaban,” “apixaban,” “edoxaban,” “real-world,” “claim,” and “observational study.” No language limitations were used. The search strategy, which was comprised of keywords and Medical Subject Heading terms, were primarily developed in a PubMed search and then applied to the other searches (Supplemental Digital Content Table I, http://links.lww.com/MD/G348). Manual searches were also conducted from the reference lists of the included studies and relevant review articles to find potentially eligible studies. We followed the Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) extension statement for reporting of systematic reviews incorporating NMA.[19] As the nature of meta-analysis of published studies, no ethical approval was warranted.

2.2. Study selection, data extraction, and quality assessment

Studies were included if they met the following criteria: observational cohort studies in Asian populations with NVAF that compared the efficacy and safety of oral anticoagulants, which included warfarin and any of the following 4 NOACs: dabigatran, rivaroxaban, apixaban, or edoxaban; reported at least one of the following clinical outcomes: IS, stroke/systemic embolism (SSE), major bleeding, gastrointestinal (GI) bleeding, intracerebral hemorrhage (ICH), myocardial infarction (MI), or all-cause mortality; and the application of the Cox proportional hazard model with or without propensity score matching (PSM), propensity score adjustment or inverse probability of treatment weighting (IPTW). Studies were excluded if enrolled patients had valvular AF, or non-Asian populations were included. The selection of individual studies was independently determined by 2 investigators (JJM and KSM). Data extraction and quality assessments of the included studies were also performed by the same 2 investigators. Any disagreement during study selection, data extraction, or quality assessment was resolved by consensus.

Eligible studies were evaluated for possible overlap according to geographic location, chronological period, sample size, outcome, and type of statistical analysis. For the studies from the same databases with overlapping patients, we opted for the study with the longest follow-up period, the larger sample size, or a recent update.

The publication year, study country, study period, data source, statistical method, number of patients in each treatment arm, type or dosage of the NOACs (ie, total-, standard-, or low-dose), CHA2DS2-VASc score, (adjusted) hazard ratios, and 95% confidence intervals (CIs), if possible, for the outcomes of interest were extracted using a pre-determined format. The primary outcomes of efficacy and safety were IS and major bleeding, respectively. The secondary efficacy outcome was SSE, MI, and all-cause mortality, and the secondary safety outcomes were GI bleeding and ICH. Due to variations in the definition and characterization of major bleeding, each original study’s definition was used accordingly.

Quality assessments were conducted using the Risk of Bias Assessment Tool for Non-Randomized Studies.[20]

2.3. Statistical analyses

The NMA was performed based on a frequentist method with random-effects model to compare the relative effects of the 4
NOACs versus warfarin. Outcomes were compared through both direct and indirect or mixed evidence using the hazard ratios and 95% CIs. P values were then created to rank these interventions. For each outcome, the interventions with higher P values were considered more desirable compared to the others.[21,22] The hierarchy of the treatments was determined using the P value, where a larger P score value represented a better rank. Clustered ranking plots using the P score were created to summarize 2 different outcomes simultaneously.

The inconsistency of the NMA was assessed in 2 ways: global inconsistency and local inconsistency. Global inconsistency was assessed using the design-by-treatment interaction model to calculate inconsistency in the network as a whole.[22] Local inconsistency was assessed only when available using a loop-specific approach to calculate the difference between direct and indirect evidence in each closed loop.[23]

For conventional pair-wise meta-analyses as direct evidence, we measured the pooled effects using the generic inverse variance method with a random-effects model. If at least 2 studies were present, a conventional meta-analysis was performed, that is, each NOAC was compared with the other NOACs or with warfarin. We used Cochrane Q and $I^2$ statistics to estimate the extent of heterogeneity. $I^2$ percentages of 25%, 50%, and 75% were indicative of low, moderate, and high heterogeneities, respectively.

Subgroup analyses regarding the available clinical outcomes were separately performed according to the dose range of the 4 NOACs ("standard-" and "low-dose"). The total dose included all patient groups regardless of dosage. It was not possible to confirm whether the dosage used was a regular or a reduced dose; therefore, the categories standard-dose and low-dose were used. Because the categorization of standard- and low-dose rivaroxaban was unequal in several studies, rivaroxaban was classified according to the dose criteria defined and applied in each study. Additionally, body weight and serum creatinine data were not available; therefore, label adherence could not be assessed in this study.

We used a comparison-adjusted funnel plot to assess network-wide publication bias. A 2-sided $P$ value <.05 was considered statistically significant. An NMA for mixed comparisons was conducted using R version 3.6 software (http://www.r-project.org), and a pair-wise meta-analysis for direct comparison was performed using the Comprehensive Meta-Analysis version 3.0 and Review Manager (RevMan) version 5.3.

3. Results

3.1. Study characteristics

Eleven studies were ultimately included in the present analysis (Fig. 1). They were performed in South Korea, Japan, China (Hong Kong), Taiwan, and Malaysia. All those included a warfarin treatment group as a comparison, and 3 studies compared all 4 NOAC treatments to warfarin.[16–18] One study compared dabigatran and rivaroxaban,[24] and one study compared the efficacy and safety of dabigatran, rivaroxaban, and apixaban.[25] Of the total 359,107 patients included in this present meta-analysis, 86,687 and 272,420 patients were classified into the warfarin and 4 NOAC treatment groups (dabigatran, n = 61,033; apixaban, n = 66,967; rivaroxaban, n = 108,024; edoxaban, n = 36,396), respectively. Low-dose dabigatran, rivaroxaban, apixaban, and edoxaban were administered to 78%, 67%, 57%, and 65% of the patients, respectively. The baseline characteristics of the included studies are listed in Table 1. There were 9 studies[16–18,24–29] with dabigatran, 6 studies[16–18,24,25,30] with rivaroxaban, 4 studies[16–18,25] with apixaban, and 4 studies[16–18,31] with edoxaban. Five studies[16–18,25,31] originated from health claims data, and 6 studies[24,26–30] from single-center registry data. As the primary statistical method, 7 studies[16–18,25,27,30,31] utilized the Cox proportional hazard model after PSM and 4 studies[24,26,28,29] utilized a multivariate Cox regression model. In the subgroup analysis according to the NOAC dosage, 6 studies[16–18,25,30,31] were allocated to

Table 1. Baseline characteristics of the included studies.

| Region | Study period | Data source | Primary statistical method | Total-dose treatments (% of low dose) | CHA2DS2 - VASC | Age |
|--------|--------------|-------------|---------------------------|--------------------------------------|-----------------|-----|
| Chan et al, 2019[18] | Taiwan | June 2012 to Dec. 2017 | NHI Database | PSM | Dabigatran 61,033 (78%) 33,022 (94%) 9952 (64%) 4577 (64%) 19,761 3.6 74.7 |
| Lee et al, 2019[27] | Korea | January 2015 to December 2017 | Korean NH | PSM | 17,745 (67%) 39,965 (58%) 22,177 (50%) 15,496 (59%) 25,420 3.56 71.0 |
| Ho et al, 2012[26] | Hong Kong | January 2020 to November 2011 | Single-center cohort | Multivariable Cox regression | NA | 804 (51%) |
| Jeong et al, 2019[30] | Korea | January 2014 to December 2016 | Single-center cohort | PSM | NA | 804 |
| Nagamura et al, 2016[27] | Japan | March 2011 to December 2013 | Single-center cohort | PSM | 181 (73%) |
| Koshizaka et al, 2020[25] | Japan | March 2011 to July 2016 | Health claims data | PSM (s-IPTW) | 6925 (76.2%) 16,564 (47.2%) 22,336 (57.3%) 12,262 (57.3%) |
| Chan et al, 2011[24] | Hong Kong | 2010 to 2013 | Single-center cohort | Multivariable Cox regression | 129 (100%) |
| Li et al, 2016[29] | Hong Kong | January 2008 to December 2014 | Single-center cohort | Multivariable Cox regression | 467 (67%) 669 (41%) |
| Yap et al, 2016[28] | Malaysia | January 2009 to December 2013 | Single-center cohort | Multivariable Cox regression | 500 (41%) |
| Cho et al, 2019[25] | Korea | July 2015 to December 2016 | Single-center cohort | PSM | 12,593 (75%) 21,000 (59%) 12,502 (63%) |
| Lee et al, 2013[24] | Korea | January 2014 to December 2016 | Korean NH | PSM | 0.56 (51%) |

NHI = National Health Insurance, PSM = propensity score matching, s-IPTW = inverse probability of treatment weighting with stabilized weights, NA = not available.

Implies CHADS2 score.
standard-dose regimens, and 8 studies\(^{[16–18,24,25,28,30,31]}\) to low-dose regimens.

### 3.2. Risk of bias assessment

For the majority of the studies included in our review, there was low risk of bias in the 6 domains (Supplemental Digital Content Figure 1, http://links.lww.com/MD/G348). For 2 studies\(^{[26,27]}\); however, incomplete outcome data were associated with a high risk of bias. In 4 studies\(^{[26–29]}\), the risk of bias was unclear for the selective outcome reporting and/or incomplete outcome data items because there was insufficient information to determine the level of risk.

### 3.3. Comparisons between total-dose NOACs and Warfarin

Network plots under each outcome are shown in Supplemental Digital Content Figure 2, http://links.lww.com/MD/G348. Of the 11 studies, 7\(^{[16–18,24,28–30]}\) included 1 direct comparison between the 5 different treatments concerning IS. There were 5 studies\(^{[16,18,25,27,30]}\) with no direct comparisons in terms of SSE, 7 studies\(^{[16–18,26,27,29,30]}\) with 2\(^{[17,18]}\) direct comparisons concerning major bleeding, 6\(^{[16–18,26,29,30]}\) studies with 2\(^{[17,18]}\) direct comparisons concerning GI bleeding, 6\(^{[16–18,26,28,30]}\) studies with 1\(^{[17]}\) direct comparison concerning ICH, 2\(^{[18,30]}\) studies with no direct comparison concerning MI, and 3\(^{[25,30,31]}\) studies with no direct comparison concerning all-cause mortality.

### 3.4. Ischemic stroke

All 4 NOACs significantly reduced the risk of IS in mixed comparisons with warfarin (Fig. 2A). Apixaban was associated with a lower risk compared with dabigatran and rivaroxaban (Table 2). Edoxaban also had a lower risk than rivaroxaban. Dabigatran had a higher risk than edoxaban. Comparisons between the other NOACs were insignificant. In direct comparisons to warfarin, all NOACs except dabigatran had a statistically lower risk of IS with low heterogeneity (Table 2). However, because IS was not directly compared between the 4 NOACs in the included studies, these data could not be assessed.

### 3.5. Stroke/systemic embolism

All 4 NOACs significantly reduced the risk of SSE in mixed comparisons with warfarin (Fig. 2B). There was no statistical difference between the NOACs except for the marginal lower risk of SSE with apixaban compared with dabigatran (Table 2). Direct
comparisons demonstrated that the 4 NOACs were superior to warfarin in terms of SSE (Table 2). However, there were no data concerning direct comparisons of the risk of SSE between all the NOACs; therefore, these data could not be assessed.

### 3.6. Major bleeding

All 4 NOACs were significantly associated with a lower risk of major bleeding compared with warfarin (Fig. 2C). Additionally, apixaban, edoxaban, and dabigatran were associated with a lower rate compared with rivaroxaban (Table 2). Comparisons between the other NOACs were insignificant. In direct comparisons to warfarin, the 4 NOACs showed similar trends with a wide range of heterogeneity (Table 2). In addition, there was significantly less major bleeding with apixaban than with rivaroxaban.

### 3.7. GI bleeding

Apixaban and edoxaban significantly reduced the risk of GI bleeding compared with warfarin (Fig. 2D). Dabigatran and rivaroxaban had a marginal tendency toward lower GI bleeding compared to warfarin. Apixaban had a lower risk compared with dabigatran and rivaroxaban (Table 2). Edoxaban was comparable to the other NOACs. In direct comparisons, apixaban and rivaroxaban reduced the risk of GI bleeding compared with
warfarin. Apixaban was associated with significantly less GI bleeding compared with rivaroxaban (Table 2).

### 3.8. Intracerebral hemorrhage

All 4 NOACs had significantly reduced risks of ICH in mixed comparisons with warfarin (Fig. 2E). However, dabigatran and edoxaban have lower risk compared to rivaroxaban. And apixaban has a higher risk of ICH compared to dabigatran and edoxaban (Table 2). The 4 NOACs were superior to warfarin in direct comparisons (Table 2). However, there were no data directly comparing the 4 NOACs.

### 3.9. Myocardial infarction

All 4 NOACs did not significantly reduce MI in mixed comparisons with warfarin (Fig. 2F). In direct comparison, rivaroxaban was comparable to warfarin with low heterogeneity (Table 2).

### 3.10. All-cause mortality

In mixed comparisons, all 4 NOACs did not significantly reduce all-cause mortality compared to warfarin (Fig. 2G). In direct comparison, there was no significant difference between rivaroxaban and warfarin with high heterogeneity (Table 2).

---

**Table 2**

Comparisons between the 4 NOACs and warfarin according to outcomes.

|                      | Apixaban | Dabigatran | Edoxaban | Rivaroxaban | Warfarin |
|----------------------|----------|------------|----------|-------------|----------|
| **Ischemic stroke**  |          |            |          |             |          |
| Apixaban             | Ref.     | 0.85 (0.78–0.92) | 1.07 (0.97–1.17) | 0.86 (0.80–0.93) | 0.68 (0.64–0.73) |
| Dabigatran           | –        | Ref.       | 1.26 (1.14–1.38) | 1.02 (0.94–1.09) | 0.80 (0.75–0.86) |
| Edoxaban             | –        | –          | Ref.      | 0.81 (0.74–0.88) | 0.64 (0.59–0.69) |
| Rivaroxaban          | –        | –          | –         | Ref.         | 0.79 (0.75–0.83) |
| Warfarin             | 0.79 (0.77–0.81) | 0.75 (0.60–0.94) | 0.67 (0.59–0.76) | 0.79 (0.77–0.81) | Ref. |
| **Stroke/Systemic embolism** |          |            |          |             |          |
| Apixaban             | Ref.     | 0.86 (0.75–1.00) | 0.94 (0.77–1.15) | 0.91 (0.80–1.05) | 0.66 (0.60–0.73) |
| Dabigatran           | –        | Ref.       | 1.09 (0.89–1.33) | 1.06 (0.92–1.22) | 0.77 (0.69–0.86) |
| Edoxaban             | –        | –          | Ref.      | 0.97 (0.80–1.18) | 0.71 (0.60–0.84) |
| Rivaroxaban          | –        | –          | –         | Ref.         | 0.73 (0.66–0.80) |
| Warfarin             | 0.67 (0.60–0.73) | 0.77 (0.69–0.86) | 0.71 (0.60–0.84) | 0.73 (0.66–0.80) | Ref. |
| **Major bleeding**   |          |            |          |             |          |
| Apixaban             | Ref.     | 0.89 (0.78–1.03) | 1.00 (0.86–1.16) | 0.76 (0.66–0.87) | 0.56 (0.50–0.63) |
| Dabigatran           | 0.75 (0.49–1.16) | Ref.       | 1.12 (0.96–1.31) | 0.85 (0.74–0.98) | 0.63 (0.56–0.71) |
| Edoxaban             | 1.01 (0.85–1.22) | –          | Ref.      | 0.76 (0.65–0.88) | 0.56 (0.49–0.64) |
| Rivaroxaban          | 0.75 (0.66–0.85) | –          | –         | Ref.         | 0.74 (0.66–0.83) |
| Warfarin             | 0.56 (0.42–0.75) | 0.63 (0.56–0.70) | 0.58 (0.45–0.74) | 0.68 (0.56–0.82) | Ref. |
| **GI bleeding**      |          |            |          |             |          |
| Apixaban             | Ref.     | 0.69 (0.54–0.87) | 0.81 (0.63–1.03) | 0.65 (0.51–0.82) | 0.56 (0.46–0.69) |
| Dabigatran           | 0.53 (0.21–1.31) | Ref.       | 1.17 (0.91–1.51) | 0.94 (0.74–1.20) | 0.82 (0.67–1.00) |
| Edoxaban             | 0.83 (0.67–1.04) | –          | Ref.      | 0.8 (0.63–1.03) | 0.69 (0.56–0.86) |
| Rivaroxaban          | 0.56 (0.32–0.99) | –          | –         | Ref.         | 0.86 (0.71–1.05) |
| Warfarin             | 0.56 (0.35–0.88) | 0.82 (0.62–1.07) | 0.65 (0.41–1.04) | 0.83 (0.76–0.91) | Ref. |
| **ICH**              |          |            |          |             |          |
| Apixaban             | Ref.     | 1.47 (1.24–1.75) | 1.60 (1.32–1.95) | 0.97 (0.83–1.13) | 0.68 (0.59–0.77) |
| Dabigatran           | –        | Ref.       | 1.09 (0.88–1.34) | 0.66 (0.56–0.78) | 0.46 (0.39–0.54) |
| Edoxaban             | –        | –          | Ref.      | 0.61 (0.50–0.73) | 0.42 (0.35–0.50) |
| Rivaroxaban          | –        | –          | –         | Ref.         | 0.70 (0.61–0.79) |
| Warfarin             | 0.65 (0.52–0.82) | 0.45 (0.36–0.57) | 0.50 (0.31–0.78) | 0.65 (0.52–0.82) | Ref. |
| **MI**               |          |            |          |             |          |
| Apixaban             | Ref.     | 0.83 (0.34–2.01) | 1.25 (0.44–3.55) | 0.87 (0.37–2.07) | 0.71 (0.37–1.37) |
| Dabigatran           | –        | Ref.       | 1.51 (0.55–4.17) | 1.06 (0.46–2.42) | 0.86 (0.47–1.58) |
| Edoxaban             | –        | –          | Ref.      | 0.70 (0.26–1.89) | 0.57 (0.25–1.29) |
| Rivaroxaban          | –        | –          | –         | Ref.         | 0.81 (0.46–1.43) |
| Warfarin             | –        | –          | –         | Ref.         | 0.81 (0.46–1.43) |
| **All-cause Mortality** |        |            |          |             |          |
| Apixaban             | Ref.     | 0.96 (0.19–4.79) | 1.02 (0.20–5.17) | 1.40 (0.33–5.83) | 0.73 (0.23–2.27) |
| Dabigatran           | –        | Ref.       | 1.06 (0.21–5.38) | 1.45 (0.35–6.06) | 0.76 (0.24–2.37) |
| Edoxaban             | –        | –          | Ref.      | 1.37 (0.32–5.82) | 0.72 (0.22–2.28) |
| Rivaroxaban          | –        | –          | –         | Ref.         | 0.52 (0.22–1.24) |
| Warfarin             | –        | –          | –         | Ref.         | 0.52 (0.22–1.24) |

Each of the results was calculated by comparing oral anticoagulant regimens in the column with those in the row. The top half of the table depicts the results of mixed comparisons (network meta-analysis) with the column as a reference, whereas the bottom half of the table depicts the results of direct comparisons (pair-wise meta-analysis) with the row as a reference. Statistically significant HRs are presented in bold. For direct comparisons, heterogeneity is presented († for low, ‡ for moderate, and § for high) — no direct comparison. GI = gastrointestinal, ICH = intracerebral hemorrhage, MI = myocardial infarction, NOACs = non-vitamin K antagonists.
3.11. Clustered ranking of outcomes between the 4 NOACs and warfarin

With regard to the prevention of IS, edoxaban ranked the best and followed by apixaban (P scores .98 and .77, respectively) (Fig. 2A). In SSE, P score was highest in the apixaban followed by edoxaban (P scores .90 and .68, respectively) (Fig. 2B). With regard to the prevention of major bleeding, apixaban and edoxaban ranked the best and second best (P scores .86, and .86, respectively) (Fig. 2C). For prevention of GI bleeding, apixaban ranked the best and followed by edoxaban (P scores .99 and .72, respectively) (Fig. 2D). With regard to the prevention of ICH, edoxaban and dabigatran ranked the best and second best (P scores .95 and .80, respectively) (Fig. 2E). A total of 6 clustered ranking plots were presented using the P score in combination with one of the efficacy outcomes (IS or SSE) and one of safety outcomes (major bleeding, GI bleeding, or ICH) (Fig. 3). Edoxaban and apixaban were generally considered to be good balanced options in terms of efficacy and safety outcomes. Dabigatran, with the second highest P score, appeared to be superior in ICH prevention.

3.12. Subgroup analysis

3.12.1. Comparisons between standard-dose NOACs and warfarin. Six studies[16-18,25,30,31] were included, and network plots for each outcome are presented in Supplemental Digital Content Figure 3, http://links.lww.com/MD/G348. Compared with warfarin, all the NOACs were associated with a lower risk of IS and major bleeding (Fig. 4). Apixaban, dabigatran, and rivaroxaban had a lower risk of SSE than warfarin. The NOACs also had superior safety profiles compared with warfarin: apixaban and edoxaban in terms of GI bleeding and apixaban, dabigatran, and rivaroxaban in terms of ICH. Although not significant, edoxaban trended toward a lower risk of SSE; dabigatran and rivaroxaban toward a lower risk of GI bleeding; and rivaroxaban toward a lower risk of ICH (Supplemental Digital Content Table 2, http://links.lww.com/MD/G348). Compared with rivaroxaban, apixaban was associated with a lower risk of IS, SSE, major bleeding, and GI bleeding; edoxaban was associated with a lower risk of major bleeding, GI bleeding, and ICH; and dabigatran was associated with a lower risk of ICH. Apixaban was associated with significantly less GI bleeding than dabigatran. With regards to MI, all NOACs did not significantly reduce MI compared with warfarin. In direct comparisons between the 4 NOACs and warfarin (Supplemental Digital Content Table 2, http://links.lww.com/MD/G348), apixaban was associated with a lower risk of IS, SSE, and major bleeding. Edoxaban was associated with a lower risk of GI bleeding and ICH. Rivaroxaban was associated with a lower risk of IS and SSE. Dabigatran was associated with a lower risk of IS, SSE, major bleeding, and ICH.
Apixaban ranked highest in terms of efficacy (IS, SSE and MI), whereas edoxaban ranked highest in terms of safety. Dabigatran had the second highest P score for IS and ICH.

3.12.2. Comparisons between 4 low-dose NOACs and warfarin. Eight studies\textsuperscript{[16–18,24,25,28,30,31]} were included, and network plots for each outcome are presented in Supplemental Digital Figure 4, http://links.lww.com/MD/G348. Compared with warfarin, all 4 NOACs were associated with a lower risk of SSE. Dabigatran and rivaroxaban were associated with a lower risk of IS; apixaban with a lower risk of major bleeding; and dabigatran, edoxaban, and rivaroxaban with a lower risk of ICH (Fig. 5). In mixed comparisons between the 4 NOACs, there was no significant difference between them (Supplemental Digital Table 3, http://links.lww.com/MD/G348). When directly compared with warfarin, the 4 NOACs ranked higher for IS and SSE (Supplemental Digital Table 3, http://links.lww.com/MD/G348). However, only apixaban was associated with a lower risk of major bleeding. All the NOACs except apixaban were associated with a lower risk of ICH. No comparison between all 4 of the NOACs was found.

Edoxaban ranked highest in terms of IS, SSE, GI bleeding, and ICH prevention and the second highest in terms of major bleeding prevention; however, IS, major bleeding, and GI bleeding prevention were all nonsignificant. For major bleeding prevention, apixaban had the highest P score. Dabigatran ranked second in IS and ICH prevention.

3.12.3. Assessment of heterogeneity and inconsistency in NMA. There was no significant global or local inconsistency between the direct and indirect estimates in IS and ICH. With regard to major bleeding and GI bleeding, global inconsistency was observed, whereas local inconsistency was not. Global inconsistency was not observed in SSE and MI; however, local inconsistency was not performed due to an incomplete network between the drugs. With regard to all-cause mortality, global inconsistency was observed, whereas local inconsistency was not acquired due to an incomplete network between the drugs (Supplemental Digital Content Figure 2, http://links.lww.com/MD/G348). For standard-dose regimens, global and local inconsistencies were not observed for any of the outcomes except SSE and MI. In SSE and MI, global inconsistency was not observed; however, local inconsistency was not acquired due to incomplete network between the drugs (Supplemental Digital Content Figure 3, http://links.lww.com/MD/G348). For the low-dose regimen, global inconsistency was not observed for IS, SSE,
or ICH. Local inconsistencies were not observed for any outcome due to incomplete networks between the drugs (Supplemental Digital Content Figure 4, http://links.lww.com/MD/G348).

3.12.4. Assessment of publication bias. The Begg-Mazumdar rank correlation test showed no significant publication bias in any meta-analysis (all P values > .05) except for major bleeding (P = .01) for total-dose and GI bleeding (P = .02) for standard-dose regimens. We could not perform a publication bias test for GI bleeding at low dose (n = 4), MI at total (n = 2) and standard doses (n = 2), and all-cause mortality at total dose (n = 3) due to the small number of included studies.

4. Discussion
In the present study, we have provided updated efficacy and safety profiles for all 4 NOACs with >350,000 Asian patients with NVAF from real-world studies. All 4 NOACs had better efficacy (IS and SSE) and safety (major bleeding, GI bleeding, and ICH) than warfarin in the total study population. Similar trends were sustained when standard- and low-dose regimens of the 4 NOACs were compared with warfarin. To the best of our knowledge, we have demonstrated for the first time that apixaban and edoxaban might be relatively better and more well-balanced treatment options for Asian patients with NVAF, irrespective of dose regimens.

Previous NMA has reported better efficacy and/or safety with apixaban compared with dabigatran and rivaroxaban among Asians with NVAF, although these studies did not include edoxaban. Recent NMA has also reported that apixaban is superior to other NOACs in terms of reducing SSE, whereas edoxaban is safer than other NOACs. Another pair-wise meta-analysis in Asian populations and NMA based on Asian and Western populations also found that apixaban had the most favorable balance of safety and efficacy. These findings were consistent with our results, especially in terms of the comparative advantage of apixaban in the standard-dose regimen. Additionally, in the apixaban group, the higher proportion of standard dose treatment (43%) may be partial explanation of better outcomes than dabigatran or rivaroxaban.

With regard to the beneficial effect of edoxaban over warfarin, dabigatran, and rivaroxaban, there might be several explanations. In the ENGAGE AF-TIMI 48 substudy, standard-dose edoxaban had better outcomes for SSE events than the well-managed warfarin group irrespective of ethnicity, whereas the same dose of edoxaban in Asians showed a more favorable but nonsignificant trend compared with that in Westerners with respect to IS. In our study, edoxaban showed a better protective effect for IS compared with warfarin, dabigatran, and...
rivaroxaban. Indeed, edoxaban was the most effective in terms of safety profiles. One possible reason is that our study only included Asians in real-world settings. Although we could not evaluate TTR in the warfarin group from this study, it is possible that warfarin control was relatively poor in these real-world populations, as has been reported in previous studies.[1,34,35] The difference in the effects of edoxaban and warfarin could be intensified in real-world datasets. In addition, because Asian patients have lower body weight and body mass index than Western patients, there is a possibility that the preserved efficacy and better safety profile are due to lower trough concentrations and anti-Factor Xa activity even at standard doses of edoxaban.

In fact, a higher proportion of standard dose edoxaban was observed in this study; 35% of patients were prescribed standard-dose edoxaban, whereas 22% and 33% of patients were prescribed standard-dose dabigatran and rivaroxaban, respectively. Moreover, a reduction in dose could preserve the efficacy of edoxaban while increasing its safety.[36]

The significance and magnitude of low-dose NOACs on outcomes appear to be diminished compared with standard-dose regimens. In fact, only apixaban reduced major bleeding and no NOACs reduced the risk of GI bleeding. In addition, only low-dose dabigatran and rivaroxaban reduced the risk of IS, in contrast to the effect of standard-dose regimens of all the NOACs. This can be attributed to the relatively small sample size and subsequent wide range of CIs when each drug and warfarin were compared. Most importantly, this might be associated with some immeasurable confounding factors such as decisions made by physicians. Physicians often use low-dose NOAC for patients with a high risk of bleeding, and this preference is more reflected in studies using real-world data. Although reducing the dose of NOACs might be considered a way to increase safety by lowering the risk of bleeding in fragile patients, off-label underdosing of NOACs has been shown to be associated with an increased risk of thrombotic events including stroke or systemic embolism, without any safety benefits.[37–39]

Our research has several strengths compared with previous NMAs. First, our NMA is based on the latest Korean, Taiwanese, and Japanese claims data directly evaluating the efficacy and safety of 4 NOACs versus warfarin in real-life situations with head-to-head comparisons. Second, to reduce the influence of confounding factors in real-world data, our analysis was based on studies comparing warfarin and the 4 NOACs using PSM or multivariate analyses. Third, this was the first NMA performed according to NOAC dosages: subgroup analyses were performed to compare the effect of NOACs versus warfarin according to standard- and low-dose groups.

Our study had some limitations. First, since this study is an NMA using real-world data, lack of control for unknown confounders in the derived data may exaggerate the bias for the results. Especially, results based mainly on health claims data are susceptible to several biases because of coding errors, missing data, and a lack of clinically relevant data[40] such as quality of anticoagulation control in the warfarin group, compliance, and label adherence of NOACs. Because it is more difficult for Asian patients to maintain target international normalized ratio levels while taking warfarin than Western patients, their TTRs are often lower than those of Western patients. Thus, the effectiveness of the NOACs may have been overestimated. In addition, label adherence could not be confirmed because bodyweight and/or serum creatinine clearance was not known. Therefore, it was not possible to determine whether the appropriate dosage was used, and the patients were therefore divided into standard- and low-dose groups. A recent observational study demonstrated that inadequate apixaban dosing was not clinically effective in terms of stroke protection, as compared with warfarin.[40] However, low-dose dabigatran regardless of guideline-concordant use showed similar efficacy and safety compared with standard-dose dabigatran.[41] Considering that, at low doses, only dabigatran and rivaroxaban were associated with a decreased risk of IS in our study, it can be estimated that the off-label 50% dose reduction of apixaban and edoxaban does not guarantee sufficient IS prevention. Second, because only a few studies reported direct comparisons, some mixed and direct comparison results were different, affecting the heterogeneity and inconsistency of our results. Third, there was no comparison between standard-dose and low-dose regimens due to the lack of comparative real-world data. Therefore, our results should be interpreted with caution, and additional large-scale data and analyses in the future should be performed to help to determine the optimal NOAC and dosage.

5. Conclusions

Our present updated NMA has provided new insights into the efficacy and safety of NOACs in Asian patients with NVAF. Our results suggest that, compared with other NOACs and warfarin, edoxaban, and apixaban offered a favorable balance of efficacy and safety. However, considering the limitations of real-world data, large clinical trials are needed to confirm these results.

Acknowledgments

The authors thank Eun-Ji Kang from the Medical Library at Korea University for searching for abstracts and articles related to this study.

Author contributions

Conceptualization: Seung Min Kim, Ji-Sung Lee, Jin-Man Jung.
Data curation: Seung Min Kim, Eun-Tae Jeon, Jin-Man Jung, Ji-Sung Lee.
Formal analysis: Jin-Man Jung, Ji-Sung Lee.
Funding acquisition: Jin-Man Jung.
Investigation: Seung Min Kim, Jin-Man Jung, Ji-Sung Lee.
Methodology: Jin-Man Jung, Ji-Sung Lee.
Supervision: Jin-Man Jung, Ji-Sung Lee.
Visualization: Seung Min Kim, Eun-Tae Jeon, Jin-Man Jung, Ji-Sung Lee.
Writing – original draft: Seung Min Kim, Jin-Man Jung, Ji-Sung Lee.
Writing – review & editing: Seung Min Kim, Jin-Man Jung.

References

[1] Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014;111:789–97.
[2] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–8.
[3] Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920–5.
[4] Chiang CE, Zhang S, Tse HF, Teo WS, Omar R, Siriratanathathorn C. Atrial fibrillation management in Asia: from the Asian expert forum on atrial fibrillation. Int J Cardiol 2013;164:21–32.
[5] Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 2011;124:314-23.

[6] Bang OY, Hong KS, Heo JH. Asian patients with stroke plus atrial fibrillation and the dose of non-vitamin K oral anticoagulants. J Stroke 2016;18:169-78.

[7] Mathur R, Pollara E, Hull S, Schofield P, Ashworth M, Robson J. Ethnicity and stroke risk in patients with atrial fibrillation. Heart 2013;99:1087–92.

[8] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:e199–267.

[9] Hong KS, Kim YK, Bae HJ, et al. Quality of anticoagulation with warfarin in Korean patients with atrial fibrillation and prior stroke: a multicenter retrospective observational study. J Clin Neurol 2017;13:273–80.

[10] Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol 2015;180:246–54.

[11] Xue Z, Zhou Y, Wu C, Lin J, Liu X, Zhu W. Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidence from the real-world data. Heart Fail Rev 2020;25:957–64.

[12] Xue Z, Zhang H. Non-vitamin K antagonist oral anticoagulants versus warfarin in Asians with atrial fibrillation: meta-analysis of randomized trials and real-world studies. Stroke 2019;50:2819–28.

[13] Liu X, Huang M, Ye C, Zeng J, Zeng C, Ma J. The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: a PRISMA-compliant article. Medicine (Baltimore) 2020;99:e21025.

[14] Xiong Q, Wang C, Liu H, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in Asians with nonvalvular atrial fibrillation: a network meta-analysis. Clin Appl Thromb Hemost 2019;25:107602961985188.

[15] Zhang J, Tang J, Cui X, et al. Indirect comparison of novel oral anticoagulants among Asians with non-valvular atrial fibrillation in the real world setting: a network meta-analysis. BMC Cardiovasc Disord 2019;19:182.

[16] Kohsaka S, Katada J, Saito K, et al. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. Open Heart 2020;7:e001232.

[17] Lee SR, Choi EK, Kwon S, et al. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. Stroke 2019;50:2245–51.

[18] Kim SY, Park JE, Lee YJ, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013;66:608–14.

[19] Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–84.

[20] Kim YH, Lee HF, Lee JC, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013;66:608–14.

[21] Rucker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 2015;15:58.

[22] Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 2013;33:641–56.

[23] Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932–44.

[24] Li WH, Huang D, Chiang CE, et al. Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project. Clin Cardiol 2017;40:222–9.

[25] Cho MS, Yun JE, Park JJ, et al. Outcomes after use of standard- and low-dose non-vitamin K oral anticoagulants in asian patients with atrial fibrillation. Stroke 2019;50:110–8.

[26] Ho JC, Chang AM, Yan BP, Yu CM, Lam YY, Lee VW. Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. Clin Cardiol 2012;35:E40–45.

[27] Naganuma M, Shiga T, Nagao T, Suzuki A, Murasaki K, Hagiwara N. Effectiveness and safety of dabigatran versus warfarin in “real-world” Japanese patients with atrial fibrillation: a single-center observational study. J Arrhythm 2017;33:107–10.

[28] Chan PH, Huang D, Hui JJ, et al. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm 2016;13:366–73.

[29] Yap LB, Eng DT, Sivalingam L, et al. A comparison of dabigatran with warfarin for stroke prevention in atrial fibrillation in an Asian population. Clin Appl Thromb Hemost 2016;22:792–7.

[30] Jeong HK, Lee KH, Park HW, et al. Real world comparison of rivaroxaban and warfarin in korean patients with atrial fibrillation: propensity matching cohort analysis. Chonnam Med J 2019;55:54–61.

[31] Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH. Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol 2019;72:838–53.

[32] Antz C, Doundoulakis I, Akrivos E, et al. Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis. Scand Cardiovasc J 2019;53:48–54.

[33] Yamashita T, Koretsune Y, Yang Y, et al. Edoxaban vs. warfarin in East Asian patients with atrial fibrillation—an ENGAGE AF-TIMI 48 subanalysis. Circ J 2016;80:860–9.

[34] Oh S, Goto S, Accetta G, et al. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFED-AF registry. Int J Cardiol 2016;223:543–7.

[35] Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013;2:e000067.

[36] Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385:2288–95.

[37] Lee SR, Lee YS, Park JS, et al. Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of asian patients with atrial fibrillation. J Korean Med J 2019;60:277–84.

[38] Steinberg BA, Shrader P, Thomas L, et al. Off-Label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol 2016;68:2597–604.

[39] Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017;69:2779–90.

[40] Cho MS, Yun JE, Park JJ, et al. Pattern and impact of off-label underdosing of non-vitamin-k antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing. Am J Cardiol 2020;125:1332–8.

[41] Lee KH, Park HW, Lee N, et al. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation. Europace 2017;19:iv1–9.